Breast Ultrasound and Mammography in Screening Women at High Risk for Breast Cancer
NCT ID: NCT00072501
Last Updated: 2012-10-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
INTERVENTIONAL
2004-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This clinical trial is studying breast ultrasound to see how well it works compared to mammography in detecting cancer in women who are at high risk for breast cancer.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary
* Determine the diagnostic yield of whole breast bilateral screening ultrasound and mammography for the detection of breast cancer in women at high risk for breast cancer.
* Determine the cancer detection yield of a single contrast-enhanced magnetic resonance imaging (MRI) examination after 3 rounds of annual screening with ultrasound and mammography in these participants. (MRI component of the study)
Secondary
* Determine the independent sensitivity and specificity of these screening methods in these participants.
* Correlate performance of these screening methods with selected participant characteristics (e.g., breast density and heterogeneity of the parenchyma).
* Validate the sonographic classification of lesions as "probably benign" and estimate the rate of malignancy in participants screened with these methods.
* Determine the cost effectiveness associated with screening breast ultrasound, in terms of radiologist and resource time performing the exam and the induced cost of screening ultrasound (e.g., follow-up and biopsy).
* Determine the reproducibility of lesion identification, measurement of lesion diameters, and volume and recording of lesion location on ultrasound in these participants.
* Determine the size, type, grade, and nodal status of cancers seen only on MRI in these participants. (MRI component of the study)
* Estimate the rate of benign biopsies and short interval follow-up induced only by MRI in these participants. (MRI component of the study)
* Determine the cost effectiveness of MRI, including induced costs of unnecessary biopsies and follow-up. (MRI component of the study)
* Compare the agreement among multiple examiners in sonographic, mammographic, and MRI feature analysis (using terms from the BI-RADS® lexicon) and final assessment (e.g., estimated probability of malignancy and/or recommendation for biopsy) in the enriched set of diagnostic training cases with consensus and histopathologic reference standards.
OUTLINE: This is a randomized, multicenter study. Participants are randomized to 1 of 2 screening arms.
* Arm I: Participants undergo physician-performed bilateral whole breast ultrasound (US) followed by mammogram within 2 weeks.
* Arm II: Participants undergo mammogram followed by physician-performed bilateral whole breast US within 2 weeks.
In both arms, participants with negative or benign findings are rescreened according to their screening arm at 1 and 2 years. Participants with "probably benign" findings are rescreened at the 6-month follow-up visit. Participants with findings that are suspicious or highly suggestive of malignancy are recommended for biopsy.
A subset of participants\* in both arms undergo contrast-enhanced breast MRI within 4 weeks after completion of the 2-year screening US and mammogram. Participants with "probably benign" findings seen only on MRI may undergo an additional breast MRI at the 6-month follow-up visit. Participants with additional suspicious lesions seen only on MRI undergo second-look targeted US for biopsy guidance or MRI-guided vacuum-assisted biopsy after completion of any biopsies or additional views prompted by the 2-year screening US and mammogram visit.
NOTE: \*No diagnosis of metastatic cancer of any type since entering this clinical trial.
Participants are followed annually for 3 years.
PROJECTED ACCRUAL: A total of 2,808 participants will be accrued for this study within 2 years.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SCREENING
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
breast imaging study
comparison of screening methods
magnetic resonance imaging
radiomammography
ultrasound imaging
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Not specified
PATIENT CHARACTERISTICS:
Age
* 25 and over
Sex
* Female
Menopausal status
* Not specified
Performance status
* Not specified
Life expectancy
* Not specified
Hematopoietic
* Not specified
Hepatic
* Not specified
Renal
* Glomerular filtration rate ≥ 30 mL/min
Other
* Not pregnant or nursing
* Fertile participants must use effective contraception
* Able to undergo adequate mammography and cooperate with breast ultrasound
* No concurrent medical or psychiatric condition that would preclude biopsy
* No other malignancy within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
* No contraindications to MRI (e.g., pacemaker, aneurysm clip, or other implanted magnetic device)\*
* No claustrophobia that cannot be controlled by medication with valium, ativan, or other sedative\*
* Must have intravenous access\*
* Weight \< 300 pounds\*
* Physically able to tolerate positioning in the MRI scanner\*
* Able to undergo contrast-enhanced MRI within 4 weeks after completing both study ultrasound and mammogram at 24-month time point\*
* Agrees to undergo follow-up MRI at 6 months and/or MRI-guided vacuum-assisted biopsy or ultrasound-guided core biopsy (if needed)\* NOTE: \*MRI component of the study
PRIOR CONCURRENT THERAPY:
Biologic therapy
* Not specified
Chemotherapy
* No concurrent chemotherapy (MRI component of the study)
Endocrine therapy
* See Disease Characteristics
* Concurrent chemoprevention with tamoxifen, raloxifene, anastrozole, exemestane or other aromatase inhibitor for participants with a personal history of cancer allowed (MRI component of the study)
Radiotherapy
* See Disease Characteristics
Surgery
* See Disease Characteristics
* More than 1 year since prior fine needle aspiration, core needle biopsy, or surgical procedure
* No prior bilateral mastectomy (MRI component of the study)
* More than 1 year since prior breast surgery on the study breast(s) (MRI component of the study)
* More than 5 months since prior core biopsy of the study breast(s) (MRI component of the study)
Other
* More than 1 year since prior contrast-enhanced MRI of the breast
* More than 1 year (≥ 11 full months) since prior whole breast bilateral ultrasound
* More than 1 year since prior sonographic or mammographic contrast agent injection or tomosynthesis
* More than 2 years since prior screening contrast-enhanced MRI of the study breast(s) (MRI component of the study)
* More than 1 year since prior diagnostic contrast-enhanced MRI of the study breast(s) (MRI component of the study)
* No concurrent participation in any other breast cancer screening trial
* No concurrent participation in any other study involving breast MRI, sonographic or mammographic contrast agents, or tomosynthesis
* No concurrent dialysis
25 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
American College of Radiology Imaging Network
NETWORK
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Wendie A. Berg, MD, PhD
Role: STUDY_CHAIR
Johns Hopkins at Green Spring Station
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
USC/Norris Comprehensive Cancer Center and Hospital
Los Angeles, California, United States
Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California, United States
Invision - Radiology Imaging Associates
Greenwood Village, Colorado, United States
Radiology Associates of Atlanta
Atlanta, Georgia, United States
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
Chicago, Illinois, United States
Johns Hopkins at Green Spring Station
Lutherville, Maryland, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Mayo Clinic Cancer Center
Rochester, Minnesota, United States
Siteman Cancer Center at Barnes-Jewish Hospital
St Louis, Missouri, United States
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
Chapel Hill, North Carolina, United States
Duke Comprehensive Cancer Center
Durham, North Carolina, United States
Charles M. Barrett Cancer Center at University Hospital
Cincinnati, Ohio, United States
Radiology Consultants, Incorporated
Youngstown, Ohio, United States
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
Philadelphia, Pennsylvania, United States
Weinstein Imaging Associates
Pittsburgh, Pennsylvania, United States
Allegheny Cancer Center at Allegheny General Hospital
Pittsburgh, Pennsylvania, United States
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
Dallas, Texas, United States
M.D. Anderson Cancer Center at University of Texas
Houston, Texas, United States
Centro de Estudios Radilogicos Integrales de la Mama - Buenos Aires
Buenos Aires, , Argentina
Toronto Sunnybrook Regional Cancer Centre at Sunnybrook and Women's College Health Sciences Centre
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Berg WA, Blume JD, Cormack JB, Mendelson EB, Madsen EL; ACRIN 6666 Investigators. Lesion detection and characterization in a breast US phantom: results of the ACRIN 6666 Investigators. Radiology. 2006 Jun;239(3):693-702. doi: 10.1148/radiol.2393051069. Epub 2006 Apr 26.
Madsen EL, Berg WA, Mendelson EB, Frank GR; Investigators for ACRIN Protocol 6666. Anthropomorphic breast phantoms for qualification of Investigators for ACRIN Protocol 6666. Radiology. 2006 Jun;239(3):869-74. doi: 10.1148/radiol.2393051070. Epub 2006 Apr 26.
Berg WA. Supplemental screening sonography in dense breasts. Radiol Clin North Am. 2004 Sep;42(5):845-51, vi. doi: 10.1016/j.rcl.2004.04.003.
Berg WA. Rationale for a trial of screening breast ultrasound: American College of Radiology Imaging Network (ACRIN) 6666. AJR Am J Roentgenol. 2003 May;180(5):1225-8. doi: 10.2214/ajr.180.5.1801225. No abstract available.
Berg WA, Blume JD, Cormack JB, Mendelson EB. Training the ACRIN 6666 Investigators and effects of feedback on breast ultrasound interpretive performance and agreement in BI-RADS ultrasound feature analysis. AJR Am J Roentgenol. 2012 Jul;199(1):224-35. doi: 10.2214/AJR.11.7324.
Berg WA, Zhang Z, Lehrer D, Jong RA, Pisano ED, Barr RG, Bohm-Velez M, Mahoney MC, Evans WP 3rd, Larsen LH, Morton MJ, Mendelson EB, Farria DM, Cormack JB, Marques HS, Adams A, Yeh NM, Gabrielli G; ACRIN 6666 Investigators. Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA. 2012 Apr 4;307(13):1394-404. doi: 10.1001/jama.2012.388.
Berg WA, Blume JD, Adams AM, Jong RA, Barr RG, Lehrer DE, Pisano ED, Evans WP 3rd, Mahoney MC, Hovanessian Larsen L, Gabrielli GJ, Mendelson EB. Reasons women at elevated risk of breast cancer refuse breast MR imaging screening: ACRIN 6666. Radiology. 2010 Jan;254(1):79-87. doi: 10.1148/radiol.2541090953.
Berg WA, Sechtin AG, Marques H, Zhang Z. Cystic breast masses and the ACRIN 6666 experience. Radiol Clin North Am. 2010 Sep;48(5):931-87. doi: 10.1016/j.rcl.2010.06.007.
Berg WA, Blume JD, Cormack JB, Mendelson EB, Lehrer D, Bohm-Velez M, Pisano ED, Jong RA, Evans WP, Morton MJ, Mahoney MC, Larsen LH, Barr RG, Farria DM, Marques HS, Boparai K; ACRIN 6666 Investigators. Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. JAMA. 2008 May 14;299(18):2151-63. doi: 10.1001/jama.299.18.2151.
Berg WA, Bandos AI, Mendelson EB, Lehrer D, Jong RA, Pisano ED. Ultrasound as the Primary Screening Test for Breast Cancer: Analysis From ACRIN 6666. J Natl Cancer Inst. 2015 Dec 28;108(4):djv367. doi: 10.1093/jnci/djv367. Print 2016 Apr.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ACRIN-6666
Identifier Type: -
Identifier Source: secondary_id
CDR0000339812
Identifier Type: -
Identifier Source: org_study_id